Goat Anti-Mouse IgG Fab-FITC

Cat. No.
1015-02  
Size
1.0 mg  
Price (USD)
$80.00 
Specificity Reacts with the Fab region of mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3
Source Pooled antisera from goat hyperimmunized with mouse IgG
Cross Adsorption Mouse IgG Fc; may react with immunoglobulins from other species and the light chains of other mouse immunoglobulins
Purification Affinity chromatography on mouse IgG Fab covalently linked to agarose
Isotype Goat IgG
Isotype Control Goat IgG-FITC
Format/Conjugate FITC (Fluorescein)
Buffer Formulation Phosphate buffered saline containing 0.1% sodium azide
Concentration 1.0 mg/mL
Volume 1.0 mL
Storage & Handling 2-8°C; Avoid exposure to light
Please refer to product specific SDS
Applications
Quality tested applications for relevant formats include -
ELISA 1-4
FLISA
Recommended Dilutions Please refer to product specific Technical Bulletin
  • FLISA plate was coated with purified mouse IgG Fab and IgG Fc. Immunoglobulins were detected with serially diluted Goat Anti-Mouse IgG Fab-FITC (SB Cat. No. 1015-02).

FLISA plate was coated with purified mouse IgG Fab and IgG Fc. Immunoglobulins were detected with serially diluted Goat Anti-Mouse IgG Fab-FITC (SB Cat. No. 1015-02).
 
References
1. Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33:5578-87. (ELISA)
2. Alving CR, Beck Z, inventors; The Government of the United states of America as Represented by the Secretary of the Army, assignee. Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin. United States patent application publication US 2017/0182152 A1. 2017 Jun 29. (ELISA)
3. Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J Control Release. 2018;275:12-19. (ELISA)
4. Lee J, Park E, Min J, Sung S, Jang Y, Shin JS, et al. Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Res. 2018;46:1635-47. (ELISA)